Interim report
Page 1
The information was provided for publication on August 27, 2026. Quarterly report Q2 2026
Page 2
Quarterly report - Q22026 2 TABLE OF CONTENTS Financial overview second quarter, Group .......................................3 Financial overview for the first half of the year .................................3 Significant events during and after the quarter.. ............................... 3 Financial calendar............................................................................. 4 CEO statement. ................................................................................5 Safe point-of-care tests enable faster diagnoses .............................6 Vision, mission & Strategy. ............................................................... 7 Point-of-Care .................................................................................... 8 Groundbreaking ultra-sensitive POC technology ............................. 9 The patent portfolio single molecule counting technology .............. 10 Owners ........................................................................................... 11 The Group’s development during quarter 2 2026. ..........................12 The Parent company’s development during quarter 2 2026. ..........14 Other information.. ..........................................................................15 Group financial statements. ........................................................ 16 Income statement, Group ...............................................................16 Balance sheet, Group. ....................................................................17 Changes in shareholders equity, Group .........................................18 Cash flow statement, Group. ..........................................................19 Key ratios, Group............................................................................ 20 The parent company’s financial statements. . ........................... 21 Income statement, Parent company ...............................................21 Balance sheet, Parent company..................................................... 22 Changes in shareholders equity, Parent company .........................23 Cash flow statement, summary, Parent company ..........................24 Contact ........................................................................................... 25
Page 3
Quarterly report - Q2 2026 3 Second quarter, April 1 – June 30, 2026 Net sales amounted to 0 (0). Other operating income amounted to 2,840 (13,945) thousand SEK. Operating profit (EBIT) amounted to -8,304 (-15,346) thousand SEK. Profit after tax amounted to -8,304 (-12,740) thousand SEK. Earnings per share before and after dilution: -0.69 (-1.81) SEK. Cash flow from operating activities was 7,766 (-4,699) thousand SEK. (Figures in parentheses refer to the corresponding period in the previous year.) Significant events during the quarter Selected as semi-finalist in the ADLM 2026 Disruptive Technology Award Competition. Positive patent decision in Japan. Design freeze achieved for the Psyros instrument. Positive patent decision in the United States. Significant events after the end of the period A feasibility study, on traumatic brain injury (TBI), involving 260 patient samples demonstrated excellent results and formed the basis for the signing of a SEK 29 million development agreement with BRAINBox Solutions. First half of the year, January 1 – June 30, 2026 (Figures in parentheses refer to the corresponding period in the previous year.) Net sales amounted to 0 (0). Other operating income amounted to 4,042 (15,607) thousand SEK. Operating profit (EBIT) amounted to -18,694 (-26,281) thousand SEK. Profit after tax amounted to -18,694 (-26,281) thousand SEK. Earnings per share before and after dilution: -1.55 (-3.38) SEK. Cash flow from operating activities was -4,874 (-13,875) thousand SEK.
Page 4
Quarterly report - Q2 2026 4 Financial calendar ” November 26, 2026 Interim Report Q3 February 25, 2027 Year End Report May 26, 2027 Interim report Q1 May 26, 2027 Annual General Meeting
Page 5
Quarterly report - Q2 2026 5 CEO statement ” The second quarter of 2026 has been one of the most significant quarters in Prolight’s history. After several years of intensive product development, we have now taken a decisive step from technology verification to commercial validation. Most notably, the strong results from our study with BRAINBox Solutions have again confirmed the Psyros platform’s ability to deliver laboratory-quality performance at the point of care, generating substantially increased interest from the diagnostics industry. During the quarter, we continued our efforts to finalize and industrialize the Psyros system while also achieving important advances in both product development and intellectual property. We received positive patent notifications in two of the world’s most important markets, Japan and the United States, further strengthening the protection of our unique technology and our long-term commercial opportunities. The most important event of the quarter occurred after the reporting period when results from the traumatic brain injury (TBI) study involving 260 patient samples demonstrated excellent performance. The study showed the Psyros platform’s ability to measure TBI biomarkers with high sensitivity at the point of care while delivering performance comparable to central laboratory testing. The results were sufficiently compelling to form the basis of a development agreement with BRAINBox Solutions valued at approximately SEK 29 million. The agreement is significant for several reasons. In addition to the direct funding, it represents clear external validation of he Psyros technology by a leading company in traumatic brain injury diagnostics. The collaboration also demonstrates how rapidly new biomarkers can be implemented on our platform and highlights Psyros’ potential across multiple clinical applications beyond cardiac biomarkers. The positive study data generated using both high-sensitivity troponin assays and TBI biomarkers has contributed to a clear shift in how the market views Psyros. Discussions with potential partners are increasingly focused on commercial implementation rather than on proving the technology itself. We are seeing growing interest from diagnostic companies, industry partners and distributors who recognise the need for cost- effective point-of-care testing that delivers laboratory-quality results. This was particularly evident at ADLM 2026, one of the world’s leading congresses for laboratory medicine and diagnostics. Many meetings were conducted with potential commercial partners interested in discussing strategic collaborations and future market opportunities for the Psyros platform. This increased interest reinforces our belief that the market is seeking next-generation point-of-care capable of combining laboratory- quality performance with speed, ease of use and cost efficiency. We enter the autumn with stronger commercial momentum than ever before. Our focus going forward will be on validating manufacturing processes and initiating pilot production of the first commercial products. At the same time, discussions with potential strategic partners continue and have intensified following the positive outcomes from the BRAINBox collaboration and our presence at ADLM. Finally, I would like to thank our employees, partners and shareholders for your continued support. Lund, August 2026 Ulf Bladin CEO, Prolight Diagnostics (publ) Strong momentum following successful BRAINBox results
Page 6
Quarterly report - Q2 2026 6 Prolight Diagnostics has, over a long period, observed a sharply increasing demand for user- friendly and near-patient analysis systems, so- called Point-of-Care (“POC”) systems. A couple of examples are the mergers and acquisitions that have taken place. For example, Roche’s acquisition of LumiraDx for 295 MUSD in 2023 and bioMerieux’s purchase of Spinchip in 2025 for 138 MEUR and the purchase of Specific Diagnostics for 417 MUSD in 2022. Additionally, Thermo Fisher Scientific’s acquisition of Mesa BioTech in 2021 for USD 450 million and Abbott’s acquisition of Alere for USD 5.8 billion already in 2016 show the strong interest. Primary and elderly care, emergency departments and ambulances demand fast, reliable blood test results when the patient is first examined instead of being forced to submit blood samples to hospital laboratories and wait hours or days for results, which is currently the case. Access to point-of-care analyses is especially important in acute conditions, such as for patients exhibiting acute chest pain and suspected myocardial infarction. In these situations, it is critical to make an early and correct diagnosis and initiate adequate treatment to save lives. To meet this demand, Prolight has developed a new and flexible POC system, Psyros®, which can perform In-Vitro Diagnostic (IVD) tests with the same sensitivity and precision as hospital laboratories but with the difference that test results can be given already within ten minutes or less. By obtaining these test results early in the patient care continuum, doctors and healthcare professionals can make the correct diagnosis and prioritise adequate resources for the right patient. As a result, substantial cost savings can also be realized in the heavily burdened healthcare system. The new digital immunoassay technology, Psyros, was incorporated into Prolight in early 2022 through the acquisition of the British company Psyros Diagnostics Ltd, which has developed a new, cutting-edge POC technology for digital immunoassay. The wholly owned subsidiary Psyros Diagnostics currently has a highly competent team with long and broad experience in IVD development, especially in POC tests and POC systems. 1 European Cardiology Society´s Guidelines on Fourth Universal Definition of Myocardial infarction. The team has unique competencies and experiences vital to the company’s continued development. Prolight’s pioneering IP-protected POC technology counts individual molecules digitally from a drop of blood. This proprietary technology, which also has the possibility of multiplexing (testing several biomarkers at the same time), enables the measurement of biomarkers with extremely low detection levels (femtomolar 10-15) within approximately 10 minutes or less. To Prolight’s knowledge, there is no other existing digital POC system deemed capable of performing these analyses at extremely low concentrations with such simplicity, precision, and low production costs. The system consists of an easy-to-use disposable cartridge and a portable analysis unit. Only a drop of blood is required to perform the test. The cutting-edge technology is being used, among other applications, to develop a diagnostic POC test that measures the protein troponin with high sensitivity and accuracy to aid in the rule-in and rule-out of myocardial infarction. By measuring the biomarker troponin, which is released from the heart into the bloodstream during the acute phase of myocardial infarction, the test helps to make a rapid diagnosis. Elevated levels of the protein troponin in the blood are a sign of damage in the heart muscle cells. The test places great demands on sensitivity and precision and has a substantial global sales potential. The technology also opens up the possibilities of being able to develop and analyze new POC tests in a number of different clinical areas that were previously only possible to carry out in specialized laboratories. Prolight has been able to demonstrate that its digital ultra-sensitivity immunoassay can measure low levels of specific proteins down to single-digit nanograms per liter (ng/L) with laboratory-grade reproducibility. These concentrations are indicative of what is required to rule out myocardial infarction with high-sensitivity troponin assays1. Proof-of-performance results were obtained partly in November 2022 by measuring the levels of thyroid-stimulating hormone (TSH) in human plasma samples, partly in June 2023 by measuring high-sensitivity troponin in serum samples, and also Safe point-of-care test enable faster diagnostics
Page 7
Quarterly report - Q2 2026 7 Vision, mission & Strategy in November 2023 when the company was able to show that the system for detecting single molecules provides equivalent performance in whole blood compared to plasma, without the need to separate the cells from the sample. This reduces complexity and paves the way for an extremely competitive price level. The final development work focuses on optimizing the IP-protected POC technology for digital immunoanalysis. An extensive preclinical evaluation of approximately 30 instrument prototypes confirmed the system’s technical performance and provided a strong basis for implementing a limited number of targeted improvements focused on long-term robustness and scalability. In April 2026, the Company formally achieved design freeze for the instrument, marking a major and decisive step towards scalable manufacturing and clinical use. The completed design enables pilot production of instruments to be used for verification and validation, followed by the regulatory clinical performance study in Europe and the UK, and subsequently in the United States. In March and July 2026, positive results were announced from a collaboration with BRAINBox Solutions, a leading developer of multimodal diagnostic and prognostic tests for traumatic brain injury (TBI). The analytical evaluation in March 2026 demonstrated excellent performance for a unique combination of three TBI biomarkers, highlighting how readily new markers can be transferred onto the Psyros platform, which is based on single- molecule counting. This further strengthens the platform’s potential to improve patient care across a broad range of clinical applications. The results are consistent with previously reported preclinical data demonstrating the ability of Psyros to deliver laboratory-quality results, detecting biomarkers at extremely low concentrations within minutes using only a small sample volume. The study was fully funded by BRAINBox, headquartered in Richmond, Virginia. Based on these results, Prolight and BRAINBox advanced to the next phase of the BRAINBox funded programme, in which all three assays were evaluated using a biobank comprising 260 patient samples. The results were excellent and provided the foundation for the signing of a SEK 29 million development agreement with BRAINBox. The development agreement covers the development of advanced multiplex cartridges, software and the initial purchase of pilot instruments. The samples represent a subset of more than 2,000 samples available from BRAINBox’s ongoing pivotal registration study, HeadSMART II, which is evaluating the company’s diagnostic and prognostic test for mild traumatic brain injury, BRAINBox TBI, in preparation for regulatory submission to the U.S. Food and Drug Administration (FDA). The assay format utilizes Psyros multiplex-capable test cartridges with dry reagents, enabling scalable and cost-efficient manufacturing—an important advantage in TBI and other conditions requiring high-precision measurement of multiple analytes. Regulatory approval of the BRAINBox system would also mark the U.S. market approval of the Psyros platform, representing a key milestone for Prolight. Strategy Prolight’s strategy is to establish Psyros® as a leading and cost-effective point-of-care platform for high- sensitivity biomarker testing. The platform is initially being developed for areas with significant unmet medical needs, such as cardiovascular and neurological conditions, but has the potential to be used across a broad range of clinical applications. By enabling rapid and reliable test results close to the patient within 10 minutes, Psyros has the potential to support more efficient clinical workflows, reduce healthcare costs and improve patient outcomes. Vision Pioneering the next frontier in lifesaving diagnostic insights. Mission To make high-sensitivity biomarker testing available wherever care happens — delivering trusted results in minutes, so clinicians can act faster, health systems can operate more efficiently, and patients everywhere can achieve better outcomes.
Page 8
Quarterly report - Q2 2026 8 Point-of-Care There is an acute awareness of the value of rapid, accurate, and efficient testing near the patient. The market demands that more tests are moved out from large hospital laboratories and closer to the patient and care giver. POC tests can also help reduce healthcare costs by giving faster results and more rapid treatment. Throughout the Covid pandemic, the use of POC testing increased substantially. This led to an acute awareness of the value of rapid, simple, and efficient testing and analysis near the patient. Most companies, healthcare providers, politicians and the general public realize the value of these tests, benefitting patients, clinicians, and healthcare in general. This interest has, in turn, created a need for new technologies that can meet the challenges of more demanding tests, whilst still being competitively priced. According to Precedence research, the POC market is expected to grow from approximately USD 44,5 billion in 2025 to approximately USD 125.3 billion in 20342. The global market for cardiac biomarkers The global market for cardiac biomarkers was approximately USD 12,3 billion in 2025 and is expected to grow by approximately 7.2 percent per year until 2034, reaching an estimated USD 23.3 billion by 20343. When it comes to point-of-care (POC) testing for cardiac biomarkers, market growth is being driven by the increasing number of patients with cardiovascular diseases and growing awareness of the importance of early diagnosis. Early diagnosis enables faster and more appropriate medical interventions for the right patients. The global market for troponin The global market for troponin was approximately USD 1.6 billion in 2024 and is expected to grow by approximately 12.6 percent per year until 2033, reaching an estimated USD 4.1 billion by 20344. Trends favoring the market development of POC tests The main driving forces behind the general growth of POC tests are considered to be increased demand for central laboratory tests that are moved closer to the patient, e.g. to emergency departments, primary care, ambulances and nursing homes, rapid technical development, digitization within healthcare, increasing investments in research and development as well as an ageing population in the West. Point-of-Care – a rapidly growing global market 2 https://www.precedenceresearch.com/point-of-care-testing-market 3 https://www.imarcgroup.com/cardiac-biomarkers-market 4 https://www.insightaceanalytic.com/report/troponin-diagnostic-tests-market/3314
Page 9
Quarterly report - Q2 2026 9 Prolight is poised to deliver the most innovative and best- inclass POC systems on the market Prolight is well-positioned to deliver POC systems to satisfy several clinical unmet needs. These include high sensitive troponin, other biomarkers in many diverse clinical areas as well as assays currently not available at POC and multiplex assays for measuring several analytes simultaneously. A new ground-breaking POC technology for digital immunoassay Prolight has an entirely novel cutting-edge POC technology for digital immunoassay, which can count individual molecules from a single drop of blood. The unique IP-protected technology opens the possibility of developing several new POC tests and analysis in a wide range of clinical areas where many of them previously have only been possible to analyse in specialised laboratories. Further advantages of the digital immunoassay include its simplicity and low production costs. Detection limit at the level of PCR tests, but with significantly faster response time Today, PCR tests are recommended to confirm respiratory infections, but the response time is lengthy, sometimes several hours to days, depending on the system. By using our digital assay technology, it is possible to count individual molecules at low levels, including viral particle proteins, such as coronavirus. As a result, sensitivity and accuracy can be as good or better than PCR tests currently offered on large central laboratory instruments. The large and highly significant difference between today’s PCR tests and Prolight’s innovative digital POC platform is that the response time can be reduced to just ten minutes or less. A start of a paradigm shift in POC testing This novel technology could mark the beginning of a paradigm shift in POC testing for clinical diagnostics. Examples of possible future clinical areas are: Traumatic Brain Injury (as our cooperation with Brainbox illustrates), other Neurological pathologies, Immune system dysfunction (sepsis, autoimmune diseases), Sexually Transmitted Infections, Rapid virus detection such as in respiratory or urinary infections.. The unique and IP-proteced technology behind the digital immunoassay will make it possible to test a range of biomarkers with high sensitivity and accuracy on a single POC instrument. Groundbreaking ultra-sensitive POC technology SSeeppssiiss aanndd aaccuuttee iinnffllaammmmaattiioonnss TTrraauummaattiicc bbrraaiinn iinnjjuurryy aanndd ssttrrookkee AAccuuttee kkiiddnneeyy iinnjjuurryy CCaarrddiioovvaassccuullaarr ddiisseeaasseess AAnnaaeemmiiaa EEnnddooccrriinnee ddiisseeaasseess FFeerrttiilliittyy AAccuuttee iinnffeeccttiioonn ddiisseeaasseess CCaarrddiioommeettaabboolliicc ddiisseeaasseess DDeemmeennttiiaa PPrriimmaarryy ccaarree CCrriittiiccaall ccaarree SSeexxuuaallllyy TTrraannssmmiitttteedd IInnffeeccttiioonnss Future applications across many diverse clinical areas
Page 10
Quarterly report - Q2 2026 10 Prolight have six families of patent applications relating to the Psyros single-molecule-counting technology. The first five families are currently in the national / regional phases in a range of territories worldwide. The sixth patent application entered the PCT (patent cooperation treaty) international phase in November 2025. The first 2 patents were granted in Europe in Q2 2025 by the European Patent Office (EPO) and have now been validated in the following 17 European jurisdictions: France, Germany, Italy, Poland, Spain, United Kingdom, Austria, Belgium, Ireland, the Netherlands, Portugal, Sweden, Switzerland, Turkey, Denmark, Finland and Norway. This covers a population base of approximately 540 million people. A third patent was granted in Europe in December 2025 and has been validated in 11 European jurisdictions. The first 2 patents were granted by the Japan Patent Office (JPO) in July 2025 and April 2026 respectively. Notices of Allowance were received in July 2026 for the first patent in Korea (MOIP) and the second patent in the United States (USPTO) and these patents are expected to be granted shortly. Family 1 patent (EP3987287 and JP7700055) protects the core technology and will remain in force until 2040. Family 2 patent (EP4264266 and JP7867712) is an enhancement to the core technology and will remain in force until 2041. Family 3 patent (EP4496995) uses 2 wavelengths to enhance signal generation and will remain in force until 2042. A divisional application of family 1 patent (EP3987287) has also been filed (published as EP4549943) to seek greater scope for the core technology. The patent portfolio for the Psyros single molecule counting technology
Page 11
Quarterly report - Q2 2026 11 Owners Owners list as of 2026-06-30 Source: Euroclear The company has outstanding warrants to employees of Psyros Diagnostics Ltd. of 8,304,510 (corresponding to 83,045 shares) and 80,703 (corresponding to 80,703 shares) and can thus cause dilution. Prolight Diagnostics’ share is traded on the NGM Growth Market, under the name PRLD. Holdings 2026-06-30 Votes in % FÖRSÄKRINGSAKTIEBOLAGET AVANZA PENSION 667,841 5.54 NORDNET PENSIONSFÖRSÄKRING AB 537,343 4.46 INTEGRATED TECHNOLOGIES LTD 493,720 4.10 STEVEN ANDREW ROSS 324,782 2.70 AILEEN JANE MCGETTRICK 318,295 2.64 PAUL BRENDAN MONAGHAN 318,295 2.64 JULIE RICHARDS 318,295 2.64 SWEDBANK FÖRSÄKRING AB 226,178 1.88 SEB LIFE INTERNATIONAL ASSURANCE 225,380 1.87 FREDRIK ALPSTEN 205,766 1.71 ULF BLADIN 191,428 1.59 KIARASH FARR 126,667 1.00 Total, 12 largest owners 3,953,990 32,83 Other 8,090,792 67,17 Total 12,044,782 100.00
Page 12
Quarterly report - Q2 2026 12 The Group’s development during quarter 2, April 1 - June 30,2026 (figures in parentheses refer to the corresponding period in the previous year) REVENUE • During the product development period, the Group has no sales and net turnover. • Other income for the quarter amounted to 2,840 (13,945) thousand SEK, consisting mainly of contributions and income received from the partner BRAINBox. EXPENSES AND PROFITS • The Group’s total operating expenses during the quarter amounted to 18,104 (29,740) thousand SEK. The previous year’s figures included an impairment loss relating to the adjustment of the additional purchase price. • Other external expenses consist mainly of external expenses linked to the development of the Group’s products. • Capitalized work for own account amounted to 6,959 (449) thousand SEK and refers to costs for the Group’s product development in the English subsidiary Psyros. FINANCING AND CASH FLOW • Cash flow from operating activities amounted to 7,766 (-4,699) thousand SEK. • The Group’s cash flow from investing activities amounted to -8,328 (-595) thousand SEK and in the quarter mainly consists of capitalized development costs of 6,959 (450) thousand SEK related to the Group’s product development in the English subsidiary, Psyros. • The total cash flow for the quarter was -561 (2,706) thousand SEK. The previous year’s figures included a raised loan of 8,000 thousand SEK. • During April 2026, the English subsidiary Psyros received 11 million SEK in ”R&D tax credit”, which improved liquidity by the same amount. REVENUE • During the product development period, the Group has no sales and net turnover. • Other income for the period amounted to 4,042 (15,607) thousand SEK, consisting mainly of contributions and income received from the partner BRAINBox. The Group’s development during the first half of the year, January 1 to June 30 2026 (figures in parentheses refer to the corresponding period in the previous year)
Page 13
Quarterly report - Q2 2026 13 EXPENSES AND PROFITS • The Group’s total operating expenses during the period amounted to 38,779 (45,110) thousand SEK. The previous year’s figures included an impairment loss relating to the adjustment of the additional purchase price. • Other external expenses consist mainly of external expenses linked to the development of the Group’s products. • Capitalized work for own account amounted to 16,043 (3,222) thousand SEK and refers to costs for the Group’s product development in the English subsidiary Psyros. FINANCING AND CASH FLOW • Cash flow from operating activities amounted to –4,874 (-13,875) thousand SEK. • The Group’s cash flow from investing activities amounted to –19,133 (-3,506) thousand SEK and consists of mainly capitalized development costs of 16,043 (3,222) thousand SEK in the period linked to the Group’s product development in the English subsidiary. • The total cash flow for the period was -24,007 (-9,381). The previous year’s figures included a loan of 8,000 thousand SEK. • During April 2026, the English subsidiary Psyros received SEK 11 million in “R&D tax credit”, which improved liquidity by the same amount. • Liquid assets at the end of the period amounted to SEK 16,939 (5,652) thousand. EQUITY , RECEIVABLES AND LIABILITIES (figures in brackets refer to 2025-12-31) • Equity in the Group amounted to SEK 151,162 (169,347) thousand as of June 30, 2026. • Provisions amounted to SEK 14,419 (14,419) thousand and consist of a deferred tax liability relating to the acquired technology platform in the English subsidiary Psyros. • Current receivables amounted to SEK 9,454 (17,201) thousand. • Current liabilities amounted to 14,445 (9,664) thousand SEK. • Total assets as of June 30, 2026 amounted to 180,026 (193,431) thousand SEK and consist mainly of acquired intangible assets of 69,994 (69,994) thousand SEK relating to the technology platform in Psyros Diagnostics Ltd. and intangible assets of 73,325 (57,297) thousand SEK relating to capitalized work for own account. • The equity ratio was 84 percent (82).
Page 14
Quarterly report - Q2 2026 14 Parent Company Development during Quarter 2, April 1 – June 30, 2026 and the period January 1 -June 30, 2026 (figures in parentheses refer to the corresponding period in the previous year) REVENUE • Other income for the quarter amounted to 780 (872) thousand SEK and for the period to 1,570 (1,659) thousand SEK. The income consisted mainly of invoiced costs to Psyros for management services, exchange rate gains and distribution income from NGM. EXPENSES AND PROFITS • The company’s total operating expenses during the quarter amounted to 2,724 (2,950) thousand SEK and for the period to 5,438 (5,025) thousand SEK. The costs consisted mainly of external costs relating to consultancy costs for management services. • The result for the quarter amounted to -1,944 (-2,401) thousand SEK and for the period to -3,868 (-3,689) thousand SEK. FINANCING AND CASH FLOW • Cash flow from operating activities amounted to -6,436 (-8,529) thousand SEK during the quarter and to -29,851 (-20,870) thousand SEK during the period. • The total cash flow for the quarter amounted to -6,436 (-529) thousand SEK and for the period to -29,851 (-20,870) thousand SEK. The previous year’s figures included a loan of 8,000 thousand SEK. • Cash and cash equivalents at the end of the period amounted to 9,599 (1,960) thousand SEK. EQUITY , RECEIVABLES AND LIABILITIES (figures in brackets refer to 2025-12-31) • Equity amounted to 89,188 (93,055) thousand SEK as of June 30, 2026. • Total assets as of June 30, 2026 amounted to 92,864 (95,736) thousand SEK and consist primarily of shares in Psyros Diagnostics Ltd of 55,768 (55,768) thousand SEK. • The equity/assets ratio was 96 percent (97).
Page 15
Quarterly report - Q2 2026 15 Other information RISKS AND UNCERTAINTIES Prolight Diagnostics’ operations are exposed to a number of risks and uncertainties, which to varying degrees may have a negative impact on continued operations. Both external, operational and financial risks may negatively affect the company in the short and long term. Prolight continuously works to inventory and manage the risks and uncertainties that the operations are exposed to in order to limit risk exposure and any impact if a risk arises. A detailed description of risks and risk management can be found in the annual report for 2025. ACCOUNTING PRINCIPLES This quarterly report has been prepared in accordance with Chapter 9 of the Annual Accounts Act. Prolight applies the Accounting Board’s General Recommendations 2012:1 (K3) when preparing the company’s financial reports. AUDITOR’S REVIEW The interim report has not been subject to an auditor’s review. RELATED PARTY TRANSACTIONS No significant related party transactions have been carried out during the period except with the company’s CEO and CFO. The transactions have been carried out on market terms. OTHER The company has outstanding warrants to employees of Psyros Diagnostics Ltd. of 8,304,510 (equivalent to 83,405 shares) and 80,703 (equivalent to 80,703 shares) which may therefore result in dilution. Prolight Diagnostics’ share is traded under the ticker symbol PRLD on the NGM Growth Market.
Page 16
Quarterly report - Q2 2026 16 GROUP FINANCIAL STATEMENTS Income Statement, Summary Group Apr-Jun 2026 Apr-Jun 2025 Jan-Jun 2026 Jan-Jun 2025 Full Year 2025Amount in TSEK Operation income etc. Net Sales 0 0 0 0 0 Activated work for own account 6,959 449 16,043 3,222 15,349 Other income 2,840 13,945 4,042 15,607 26,854 Total income 9,799 14,394 20,085 18,829 42,203 Operating expenses Other external costs -11,490 -8,074 -25,801 -17,551 -53,296 Personnel costs -5,899 -5,329 -11,681 -10,804 -22,503 Depreciation/ Write-down intangible assets -712 -16,336 -1,292 -16,753 -19,635 Other operating expenses -2 -1 -3 -2 -18 Total expenses -18,104 -29,740 -38,779 -45,110 -95,452 Operating result (EBIT) -8,304 -15,346 -18,694 -26,281 -53,249 Result from financial investments Other interest income and similar items 0 0 0 0 492 Other interest expenses and similar items 0 -323 0 -323 -323 Total result from financial investments 0 -323 0 -323 169 Tax 0 2,928 0 2,928 3,372 Net loss -8,304 -12,740 -18,694 -23,676 -49,708
Page 17
Quarterly report - Q2 2026 17 Balance Sheet, Summary Group Amount in TSEK 2026-06-30 2025-06-30 2025-12-31 ASSETS Subscribed but not paid-in capital 0 100,298 90 Fixed assets Intangible assets Capaitalized expenditure on development work and similar work 143,319 117,004 127,276 Intangible assets 12 2 15 143,332 117,006 127,291 Tangible assets Equipment, tools, fixtures and fittings 10,302 5,583 8,243 10,302 5,583 8,243 Total fixed assets 153,633 122,589 135,534 Current assets Other receivables 9,351 4,045 14,409 Prepaid expenses and accrued income 103 8,115 2,792 Cash and cash equivalents 16,939 5,652 40,606 Total current assets 26,393 17,812 57,807 Total assets 180,026 240,699 193,431 Equity Share capital 120,448 70,209 120,448 New share issue in progressl 0 50,149 0 Other paid in capital 279,880 280,733 279,881 Retained earnings -230,472 -180,963 -181,274 Loss for the period -18,694 -23,676 -49,708 Total equity 151,162 196,452 169,347 Provisions Accrued tax liabilities 14,419 14,863 14,419 Total Provisions 14,419 14,863 14,419 Current liabilities Other financial liabilities 0 8,000 0 Accounts payables 7,985 9,943 6,351 Other liabilities 1,345 1,675 849 Accrued expenses and deferred income 5,116 9,766 2,464 Total current liabilities 14,445 29,384 9,664 Total equity and liabilities 180,026 240,699 193,431
Page 18
Quarterly report - Q2 2026 18 Changes in shareholders equity, Group Amount in TSEK Share capital Other paid in capital Other capital incl result for the period Total shareholders equity Shareholders equity 2026-01-01 120,448 279,880 -230,981 169,347 Loss for the period -18,694 -18,694 Foreign exchange rate adjustment 509 509 Shareholders equity 2026-06-30 120,448 279,880 -249,166 151,162 Amount in TSEK Share capital Other paid in capital Other capital incl result for the period Total shareholders equity Shareholders equity 2025-01-01 70,209 237,870 -179,794 128,285 Issue of new shares 50,239 50,148 100,387 Issuance cost -8,139 -8,139 Loss for the period -49,708 -49,708 Foreign exchange rate adjustment -1,479 -1,479 Shareholders equity 2025-12-31 120,448 279,880 -230,981 169,347
Page 19
Quarterly report - Q2 2026 19 Cash flow statement, Group Amount in TSEK Apr-Jun 2026 Apr-Jun 2025 Jan-Jun 2026 Jan-Jun 2025 Full Year 2025 OPERATING ACTIVITIES Operating result (EBIT) -8,305 -15,344 -18,694 -26,281 -53,249 Adjustment 712 85 1 292 503 7,079 Interests income 0 0 0 0 492 Cashflow from operating activities before changes in working capital -7,593 -15,259 -17,402 -25,778 -45,678 Cash flow from changes in working capital Decrease (+) / increase (-) in operating receivables 10,294 -5,409 7,747 -2,225 -4,261 Decrease (-) / increase (+) in operating liabilities 5,065 15,969 4,781 14,128 12,934 Total Cash flow from changes in working capital 15,359 10,560 12,528 11,903 8,673 Cash flow from operating activities 7,766 -4,699 -4,874 -13,875 -37,005 INVESTMENT ACTIVITIES Investment in intangible assets -6,959 -450 -16,043 -3,222 -15,349 Investment in tangible assets -1,369 -145 -3,090 -284 -4,381 Cash flow from investment activities -8,328 -595 -19,133 -3,506 -19,730 FINANCING ACTIVITIES Issue of new shares 0 0 0 0 81,437 Borrowing 0 8,000 0 8,000 0 Cash flow from financing activities 0 8,000 0 8,000 81,437 Cash flow for the period -561 2,706 -24,007 -9,381 24,702 Cash and equivalents at the beginnging of period 17,262 3,173 40,606 15,734 15,734 Exchange rate differences in cash 239 -227 340 -701 170 Cash and equivalents at the end of period 16,939 5,652 16,939 5,652 40,606
Page 20
Quarterly report - Q2 2026 20 Key ratio Group Apr-Jun 2026 Apr-Jun 2025 Jan-Jun 2026 Jan-Jun 2025 Full Year 2025 Net Sales, MSEK - - - - - Cash and equivalents, MSEK 16.9 3.1 16.9 3.1 40.6 Equity ratio, % 84 82 84 82 88 Quick asset ratio, % 395 61 183 61 598 Number of shares in the beginning of period 12,044,782 7,020,895 12,044,782 7,020,895 7,020,895 Average number of shares in the period 12,044,782 7,020,895 12,044,782 7,020,895 11,877,896 Number of shares in the end of period 12,044,782 7,020,895 12,044,782 7,020,895 12,044,782 Profit/Loss, MSEK -8.3 -12.7 -18.7 -23.7 -49.7 Earnings per share, SEK -0.69 -1.81 -1.55 -3.38 -4.13 Earnings per share after dilutions, SEK -0.69 -1.81 -1.55 -3.38 -4.13
Page 21
Quarterly report - Q2 2026 21 THE PARENT COMPANY’S FINANCIAL STATEMENTS Income Statement, Summary Parent company Apr-Jun 2026 Apr-Jun 2025 Jan-Jun 2026 Jan-Jun 2025 Full Year 2025Amount in TSEK Operation income etc. Net Sales 0 0 0 0 0 Other income 780 872 1,570 1,659 3,283 Total operation incom etc. 780 872 1,570 1,659 3,283 Operating expenses Other external costs -2,404 -2,631 -4,748 -4,338 -7,785 Personnel costs -318 -318 -686 -686 -1,423 Amortization intangible assets 0 0 0 -1,836 Other operating expenses -2 -1 -3 -2 -18 Total expenses -2,724 -2,950 -5,438 -5,025 -11,063 Operating result -1,944 -2,078 -3,868 -3,366 -7,780 Result from financial investments Write-down of investment in subsidiary 0 0 0 0 -61,385 Other interest income and similar items 0 0 0 0 492 Other interest expenses and similar items 0 -323 0 -323 -323 Total result from financial investments 0 -323 0 -323 -61,216 Net loss -1,944 -2,401 -3,868 -3,689 -68,996
Page 22
Quarterly report - Q2 2026 22 Balance Sheet, Summary, Parent company Amount in TSEK 2026-06-30 2025-06-30 2025-12-31 ASSETS Subscribed but not paid-in capital 0 100,298 90 Fixed assets Capitalized expenditure on development work and similar work 0 1,836 0 Participation in group companies 55,768 55,768 55,768 Total fixed assets 55,768 57,604 55,768 Current assets Other receivables 387 408 300 Receivables from group company 27,008 17,029 0 Prepaid expenses and accrued income 103 8,116 128 Cash and cash equivalents 9,599 1,960 39,450 Total current assets 37,096 27,513 39,878 Total assets 92,864 185,415 95,736 Equity Restricted equity 133,495 183,554 133,495 Profit or loss brought forward / Loss for the year -44,307 -24,430 -40,440 Total equity 89,188 159,124 93,055 Current liabilities Other financial liabilities 0 8,000 0 Accounts payables 1,086 7,810 406 Other liabilities 405 715 0 Accrued expenses and deferred income 2,186 9,766 2,275 Total current liabilities 3,676 26,291 2,681 Total equity and liabilities 92,864 185,415 95,736
Page 23
Quarterly report - Q2 2026 23 Changes in shareholders equity, Parent company Restricted equity Restricted equity Non resticted equity Non resticted equity Amount in TSEK Share capital Statutory reserve Share premium reserve Profit/loss brought forward Total Share- holders equity Shareholders equity 2026-01-01 120 448 13 047 266 834 -307 274 93 055 Loss for the period -3 868 -3 868 Shareholders equity 2026-06-30 120 448 13 047 266 834 -311 142 89 188 Amount in TSEK Share capital Statutory reserve Share premium reserve Profit/loss brought forward Total Share- holders equity Shareholders equity 2025-01-01 70 209 13 047 224 823 -238 278 69 801 Issue of new shares 50 239 50 149 100 388 Issuance cost -8 138 -8 138 Loss for the period -68 996 -68 996 Shareholders equity 2025-12-31 120 448 13 047 266 834 -307 274 93 055
Page 24
Quarterly report - Q2 2026 24 Cash flow statement summary, Parent company Amount in TSEK Apr-Jun 2026 Apr-Jun 2025 Jan-Jun 2026 Jan-Jun 2025 Full Year 2025 THE ONGOING OPERATIONS Operating result -1,944 -2,077 -3,868 -3,366 -7,780 Adjustment 0 12,999 0 12,998 -1,224 Interest income 0 0 0 0 493 Interest expenses 0 -323 0 -323 0 Cash flow from operating activities before changes in working capital -1,944 10,599 -3,868 9,309 -8,511 Cash flow from changes in working capital Decrease (+) / increase (-) in operating receivables -4,632 -14,144 -26,979 -25,193 -70 Decrease (-) / increase (+) in operating liabilities 140 -4,983 995 -4,986 215 Total changes in working capital -4,492 -19,128 -25,984 -30,179 145 Cash flow from operating activities -6,436 -8,529 -29,851 -20,870 -8,366 FINANCING ACTIVITIES Share issue 0 0 0 0 81,437 New loan 0 8,000 0 8,000 0 Cash flow from financing activities 0 8,000 0 8,000 81,437 Cash flow for the period -6,436 -529 -29,851 -12,870 24,620 Cash and equivalents at the beginnging of period 16,035 2,489 39,450 14,830 14,830 Cash and equivalents at the end of period 9,599 1,960 9,599 1,960 39,450
Page 25
Quarterly report - Q2 2026 25 Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction. The company’s share is traded on the NGM Growth Market marketplace, under the ticker PRLD. For further information, please contact: Prolight Diagnostics AB (publ) E-mail: info@prolightdx.com Telephone: +46 73 582 39 87 Website: www.prolightdx.com/en/ Produkten är under utveckling. Design och specifikation kan ändras för den finala produkten.